UNIVERSITY OF CALIFORNIA, IRVINE
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1965-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.uci.edu
Clinical Trials
447
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (317 trials with phase data)• Click on a phase to view related trials
HOPE Intervention for Fitness
- Conditions
- Diabetes Mellitus Type 2
- First Posted Date
- 2025-08-11
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 120
- Registration Number
- NCT07114822
- Locations
- 🇺🇸
UC Irvine, Irvine, California, United States
Mobile Health Intervention to Improve Adherence to Oral Anticancer Therapy
- Conditions
- CancerNeoplasms
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 30
- Registration Number
- NCT07073807
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center and Ambulatory Care building, Irvine, California, United States
🇺🇸UCI Health Cancer Center - Newport, Newport Beach, California, United States
🇺🇸UCI Health Pacific Breast Care Center, Newport Beach, California, United States
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
- Conditions
- Soft-tissue SarcomaTriple Negative Breast CancerNon-small Cell Lung CancerCervical CancerOvarian CancerKRAS Mutation-Related Tumors
- Interventions
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 67
- Registration Number
- NCT07064018
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center University of California, Irvine, Orange, California, United States
Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer
- Conditions
- Lung CancerDriver Mutation
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 1753
- Registration Number
- NCT07062172
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center University of California, Irvine, Orange, California, United States
Umbilical CB-NK Expressing sIL-15 & PD-L1 +/- Atezolizumab in NSCLC Pts Refractory to PD-1/PD-L1
- Conditions
- Non-small Cell Lung CancerNSCLCLung Cancer, Non-small CellLung Cancer
- Interventions
- Drug: NK-102
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 9
- Registration Number
- NCT07053007
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center University of California, Irvine, Orange, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 90
- Next
News
FDA Approves First Liquid Embolic System for Hypervascular Tumor Treatment
The FDA has granted premarket approval to the Embrace Hydrogel Embolic System, marking the first liquid embolic specifically approved for hypervascular tumor embolization based on randomized controlled trial data.
Engineered Microglia: A Revolutionary Approach to Treating Alzheimer's Disease
UC Irvine researchers have developed a groundbreaking therapy using CRISPR-edited microglia that can detect and target amyloid plaques in Alzheimer's disease, delivering therapeutic proteins precisely where needed.
INSPIRE Trials: Computerized Alerts Improve Antibiotic Selection in Hospitalized Patients by Up to 35%
• NIH-funded clinical trials involving over 316,000 patients across 92 hospitals demonstrate that computerized alerts can improve appropriate antibiotic selection by 35% for abdominal infections and 28% for skin and soft tissue infections. • The INSPIRE trials used patient-specific data to identify individuals at low risk for antibiotic-resistant infections, prompting physicians to switch from broad-spectrum to standard antibiotics when appropriate. • Researchers from UC Irvine, Harvard Pilgrim Health Care Institute, and HCA Healthcare collaborated on the studies, which could significantly reduce antibiotic resistance and improve patient outcomes nationwide.